Free Access
Issue
Méd. Intensive Réa.
Volume 27, Number 4, Juillet 2018
Médecine interne et transversalité
Page(s) 309 - 316
Section Mise au point / Update
DOI https://doi.org/10.3166/rea-2018-0045
Published online 22 June 2018
  • Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF, (2017) Ulcerative colitis. Lancet 389: 1756–1770 [CrossRef] [PubMed] [Google Scholar]
  • Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L, (2017) Crohn’s disease. Lancet 389: 1741–1755 [CrossRef] [PubMed] [Google Scholar]
  • Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ, (2010) The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol 105: 289–297 [CrossRef] [Google Scholar]
  • Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, MacMahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF, European Cs, Colitis O, (2014) Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 8: 443–468 [CrossRef] [PubMed] [Google Scholar]
  • Singh S, Singh H, Loftus EV Jr, Pardi DS, (2014) Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 12: 382–393.e381 (quiz e322) [CrossRef] [PubMed] [Google Scholar]
  • Bernstein CN, Nabalamba A, (2006) Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol 101: 110–118 [CrossRef] [Google Scholar]
  • Bernstein CN, Garland A, Peschken CA, Hitchon CA, Chen H, Fransoo R, Marrie RA, (2015) Predictors of ICU admission and outcomes 1 year post-admission in persons with IBD: a population-based study. Inflamm Bowel Dis 21: 1341–1347 [PubMed] [Google Scholar]
  • Nugent Z, Singh H, Targownik LE, Strome T, Snider C, Bernstein CN, (2016) Predictors of emergency department use by persons with inflammatory bowel diseases: a population-based study. Inflamm Bowel Dis 22: 2907–2916 [CrossRef] [PubMed] [Google Scholar]
  • Marrie RA, Garland A, Peschken CA, Hitchon CA, Chen H, Fransoo R, Bernstein CN, (2014) Increased incidence of critical illness among patients with inflammatory bowel disease: a population-based study. Clin Gastroenterol Hepatol 12: 2063–2070.e2061–2064 [CrossRef] [PubMed] [Google Scholar]
  • Bernstein CN, Nugent Z, Targownik LE, Singh H, Lix LM, (2015) Predictors and risks for death in a population-based study of persons with IBD in Manitoba. Gut 64: 1403–1411 [CrossRef] [PubMed] [Google Scholar]
  • Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D’Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P; Group SS, (2010) Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362: 1383–1395 [CrossRef] [PubMed] [Google Scholar]
  • Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ, (2008) Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134: 929–936 [CrossRef] [PubMed] [Google Scholar]
  • Ford AC, Peyrin-Biroulet L, (2013) Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 108: 1268–1276 [CrossRef] [Google Scholar]
  • Luthra P, Peyrin-Biroulet L, Ford AC, (2015) Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. Aliment Pharmacol Ther 41: 1227–1236 [CrossRef] [Google Scholar]
  • Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG, (2000) Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118: 705–713 [CrossRef] [PubMed] [Google Scholar]
  • Singh H, Nugent Z, Yu BN, Lix LM, Targownik LE, Bernstein CN, (2017) Higher incidence of Clostridium difficile infection among individuals with inflammatory bowel disease. Gastroenterology 153: 430–438.e432 [CrossRef] [PubMed] [Google Scholar]
  • Regnault H, Bourrier A, Lalande V, Nion-Larmurier I, Sokol H, Seksik P, Barbut F, Cosnes J, Beaugerie L, (2014) Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: a retrospective assessment. Dig Liver Dis 46: 1086–1092 [CrossRef] [PubMed] [Google Scholar]
  • Sokol H, Lalande V, Landman C, Bourrier A, Nion-Larmurier I, Rajca S, Kirchgesner J, Seksik P, Cosnes J, Barbut F, Beaugerie L, (2017) Clostridium difficile infection in acute flares of inflammatory bowel disease: a prospective study. Dig Liver Dis 49: 643–646 [CrossRef] [PubMed] [Google Scholar]
  • Rao K, Higgins PD, (2016) Epidemiology, diagnosis, and management of Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 22: 1744–1754 [CrossRef] [PubMed] [Google Scholar]
  • McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH, (2018) Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 19;66(7):e1–e48 [CrossRef] [PubMed] [Google Scholar]
  • Long MD, Martin C, Sandler RS, Kappelman MD, (2013) Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol 108: 240–248 [CrossRef] [Google Scholar]
  • Lanternier F, Tubach F, Ravaud P, Salmon D, Dellamonica P, Bretagne S, Couret M, Bouvard B, Debandt M, Gueit I, Gendre JP, Leone J, Nicolas N, Che D, Mariette X, Lortholary O; Research Axed on Tolerance of Biotherapies G, (2013) Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. Chest 144: 990–998 [CrossRef] [PubMed] [Google Scholar]
  • Long MD, Farraye FA, Okafor PN, Martin C, Sandler RS, Kappelman MD, (2013) Increased risk of Pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflamm Bowel Dis 19: 1018–1024 [CrossRef] [PubMed] [Google Scholar]
  • Cotter TG, Gathaiya N, Catania J, Loftus EV Jr, Tremaine WJ, Baddour LM, Harmsen WS, Zinsmeister AR, Sandborn WJ, Limper AH, Pardi DS, (2017) Low risk of pneumonia from Pneumocystis jirovecii infection in patients with inflammatory bowel disease receiving immune suppression. Clin Gastroenterol Hepatol 15: 850–856 [CrossRef] [PubMed] [Google Scholar]
  • Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM, (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098–1104 [CrossRef] [PubMed] [Google Scholar]
  • Abitbol Y, Laharie D, Cosnes J, Allez M, Nancey S, Amiot A, Aubourg A, Fumery M, Altwegg R, Michetti P, Chanteloup E, Seksik P, Baudry C, Flamant M, Bouguen G, Stefanescu C, Bourrier A, Bommelaer G, Dib N, Bigard MA, Viennot S, Hebuterne X, Gornet JM, Marteau P, Bouhnik Y, Abitbol V, Nahon S, GETAID, (2016) Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID Cohort. J Crohns Colitis 10: 1179–1185 [CrossRef] [PubMed] [Google Scholar]
  • Nahon S, Marteau P, Matuchansky C, (1998) Crohn’s disease and blood vessels. Gastroenterol Clin Biol 22: 175–187 [PubMed] [Google Scholar]
  • Landman C, Nahon S, Cosnes J, Bouhnik Y, Brixi-Benmansour H, Bouguen G, Colombel JF, Savoye G, Coffin B, Abitbol V, Filippi J, Laharie D, Moreau J, Veyrac M, Allez M, Marteau P; Groupe d’étude thérapeutique des affections inflammatoires du tube digestif, (2013) Porto-mesenteric vein thrombosis in patients with inflammatory bowel disease. Inflamm Bowel Dis 19: 582–589 [CrossRef] [PubMed] [Google Scholar]
  • Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel JF, (2014) Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis 8: 469–479 [CrossRef] [PubMed] [Google Scholar]
  • Nguyen GC, Bernstein CN, Bitton A, Chan AK, Griffiths AM, Leontiadis GI, Geerts W, Bressler B, Butzner JD, Carrier M, Chande N, Marshall JK, Williams C, Kearon C, (2014) Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology 146: 835–848.e836 [CrossRef] [PubMed] [Google Scholar]
  • Papay P, Miehsler W, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Sobala A, Weltermann A, Eichinger S, Novacek G, (2013) Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis 7: 723–729 [CrossRef] [PubMed] [Google Scholar]
  • Grainge MJ, West J, Card TR, (2010) Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 375: 657–663 [CrossRef] [PubMed] [Google Scholar]
  • Nguyen GC, Sam J, (2008) Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 103: 2272–2280 [CrossRef] [Google Scholar]
  • Novacek G, Weltermann A, Sobala A, Tilg H, Petritsch W, Reinisch W, Mayer A, Haas T, Kaser A, Feichtenschlager T, Fuchssteiner H, Knoflach P, Vogelsang H, Miehsler W, Platzer R, Tillinger W, Jaritz B, Schmid A, Blaha B, Dejaco C, Eichinger S, (2010) Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 139: 779–787.e771 [CrossRef] [PubMed] [Google Scholar]
  • Racine A, Nahon S, Jouannaud V, Caugant H, Lesgourgues B, (2008) Portal vein thrombosis in a patient with quiescent Crohn’s disease associated with hyperhomocysteinemia and antiphospholipid antibody syndrome 1-yr after an ileocecal resection. Am J Gastroenterol 103: 499–501 [CrossRef] [Google Scholar]
  • Kirchgesner J, Beaugerie L, Carrat F, Andersen NN, Jess T, Schwarzinger M ; Group Bs, (2017) Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. Gut 67:1261–1268. [CrossRef] [PubMed] [Google Scholar]
  • Singh S, Kullo IJ, Pardi DS, Loftus EV Jr, (2015) Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nat Rev Gastroenterol Hepatol 12: 26–35 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.